Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

642
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

601
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
601
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

437
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
437

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fosinopril: HIV-Associated Nephropathy (HIVAN).

Hospital pharmacy·2024
Same author

Idarucizumab.

Hospital pharmacy·2024
Same author

Fentanyl Iontophoretic Transdermal System.

Hospital pharmacy·2024
Same author

Fifty Years of Publication: Hospital Pharmacy Anniversary.

Hospital pharmacy·2024
Same author

Rolapitant.

Hospital pharmacy·2024
Same author

Zafirlukast: Chronic Urticaria.

Hospital pharmacy·2016
Same journal

Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa: A Multicenter Retrospective Cohort Study.

Hospital pharmacy·2026
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Response to Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.2K

Atorvastatin: multiple sclerosis.

Joyce A Generali1, Dennis J Cada2

  • 1Editor-in-Chief, Hospital Pharmacy , and Clinical Professor, Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy , Kansas City/Lawrence, Kansas ,

Hospital Pharmacy
|December 6, 2014
PubMed
Summary
This summary is machine-generated.

This guide helps healthcare professionals find and evaluate off-label drug uses. It provides literature references to support rational patient care decisions for unapproved drug applications.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Apr 19, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.2K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Area of Science:

  • Pharmacy
  • Pharmacology
  • Drug Utilization

Background:

  • Off-label drug use refers to prescribing medications for conditions not approved by the US Food and Drug Administration (FDA).
  • Practitioners require reliable resources to navigate the complexities of unapproved drug indications.
  • Existing literature on off-label drug use can be fragmented and challenging to access.

Purpose of the Study:

  • To introduce a practitioner-oriented resource, Off-Label Drug Facts, for information on specific unapproved drug uses.
  • To enable healthcare professionals to efficiently identify published studies on off-label drug applications.
  • To assist clinicians in determining the rationality of specific off-label drug uses in patient care scenarios.

Main Methods:

  • Extraction of relevant information from the Off-Label Drug Facts publication.
  • Literature review focused on identifying published studies concerning off-label drug uses.
  • Compilation of references to guide users to comprehensive literature.

Main Results:

  • The Off-Label Drug Facts resource provides a structured approach to off-label drug information.
  • The guide facilitates quick identification of studies supporting specific off-label drug uses.
  • References are provided to support further investigation and informed decision-making.

Conclusions:

  • Off-Label Drug Facts serves as a valuable tool for healthcare professionals managing unapproved drug indications.
  • The resource promotes evidence-based practice by directing clinicians to relevant literature.
  • Informed patient care decisions regarding off-label drug use are facilitated by this guide.